SCHEMBL3923975

SCHEMBL3923975

CCCCCCCCCCCCCCCCCC(=O)C(CCCCCCO)CCCCCCCCCCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.59
FFAR1 O14842 3/20 0.59
GPR84 Q9NQS5 8/20 0.57
PPARG P37231 7/20 0.57
PPARD Q03181 7/20 0.57
PPARA Q07869 7/20 0.57
HDAC11 Q96DB2 5/20 0.57
TSHR P16473 4/20 0.57
PTPN1 P18031 3/20 0.57
ALDH1A1 P00352 3/20 0.57
TLR2 O60603 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
FABP4 P15090 2/20 0.57
KMT2A Q03164 2/20 0.57
SLC22A6 Q4U2R8 1/20 0.57
SLC22A8 Q8TCC7 1/20 0.57
MEN1 O00255 1/20 0.57
ESR1 P03372 1/20 0.57
ALOX15 P16050 1/20 0.57
PDE4A P27815 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135514 1.00 FFAR4 (0.59) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL1962661 0.93 FFAR4 (0.67) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL6135273 0.93 FFAR4 (0.67) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL8002202 0.91 FFAR4 (0.65) FFAR4FFAR1GPR84PPARGPPARD
Stearic Acid SCHEMBL27442953 0.88 FFAR4 (0.61) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL26503035 0.88 CA2 (0.50) TSHRALDH1A1KMT2AMEN1HSD17B10
SCHEMBL29109109 0.87 FFAR4 (0.59) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL9501494 0.86 CES2 (0.59) FFAR4FFAR1
SCHEMBL5027732 0.86 CES2 (0.59) FFAR4FFAR1
SCHEMBL22016019 0.86 CES2 (0.59) FFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024136261-A1 ANTI-INFLAMMATORY OR ANTIOXIDANT COMPOSITION COMPRISING BENZYL CAFFEATE AS ACTIVE INGREDIENT 동아대학교 산학협력단 2024-06-27 WO disclosed
WO-2024136517-A1 COMPOSITION CONTAINING STURGEON MUCILAGE AS ACTIVE INGREDIENT FOR WOUND HEALING OR ACNE TREATMENT 순천향대학교 산학협력단 2024-06-27 WO disclosed
WO-2024136513-A1 COMPOSITION FOR PROMOTING HAIR GROWTH, COMPRISING STURGEON MUCUS AS ACTIVE INGREDIENT 주식회사 에셀바이오팜 2024-06-27 WO disclosed
WO-2024128690-A1 INNATE IMMUNOMODULATORY EFFECT OF GINSENG BERRY POLYSACCHARIDES IN IMMUNOSUPPRESSED STATE 강릉원주대학교산학협력단 2024-06-20 WO disclosed
US-20240197672-A1 COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2024-06-20 US disclosed
US-20240180833-A1 NANOVESICLES DERIVED FROM BACTERIA OF THE GENUS PARACOCCUS AND USE THEREOF MD HEALTHCARE INC. (KR) 2024-06-06 US disclosed
CN-117940109-A Composition for preventing bromhidrosis 持田制药株式会社 2024-04-26 CN disclosed
WO-2024085695-A1 NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION 재단법인 아산사회복지재단 2024-04-25 WO disclosed
EP-3662907-B1 ANTI-AGING OR SKIN-REGENERATING COMPOSITION COMPRISING PIPERONYLIC ACID AS EFFECTIVE INGREDIENT HESED BIO CO LTD (KR) 2024-04-17 EP disclosed
EP-4349353-A1 LACTOBACILLUS RHAMNOSUS-DERIVED VESICLE AND USES THEREOF MD Healthcare Inc. (KR) 2024-04-10 EP disclosed
US-20060222616-A1 Cosmetic composition comprising a and a lipopeptide KANEKA CORPORATION (JP) 2006-10-05 US disclosed
EP-1689494-A1 AGENT FOR SKIN EXTERNAL USE CONTAINING SALT OF ASCORBIC ACID DERIVATIVE, METHOD FOR STABILIZING THE AGENT FOR SKIN EXTERNAL USE, AND STABILIZER Showa Denko K.K. (JP) 2006-08-16 EP disclosed
EP-1660025-A1 COSMETIC COMPOSITION CONTAINING A POLYOXYETHYL COMBINATION AND A LIPOPEPTIDE Showa Denko K.K. (JP) 2006-05-31 EP disclosed
WO-2005102267-A1 AGENT FOR SKIN EXTERNAL USE CONTAINING TOCOPHEROL DERIVATIVE, ASCORBIC ACID DERIVATIVE AND SURFACE ACTIVE AGENT HAVING LIPOPEPTIDE STRUCTURE SHOWA DENKO K.K. (JP) 2005-11-03 WO disclosed
WO-2005094777-A1 EXTERNAL PREPARATION FOR SKIN SHOWA DENKO K.K. (JP) 2005-10-13 WO disclosed
WO-2005095462-A1 MOISTURE RETENTION POLYMER COMPOUND SHOWA DENKO K.K. (JP) 2005-10-13 WO disclosed
US-20050220744-A1 Polysaccharide/functional compound complex SHOWA DENKO K.K. 2005-10-06 US disclosed
WO-2005089708-A1 OIL-IN-WATER EMULSIFIED COMPOSITION, AND EXTERNAL PREPARATION FOR SKIN AND COSMETICS USING THE COMPOSITION SHOWA DENKO K.K. (JP) 2005-09-29 WO disclosed
WO-2005034903-A1 AGENT FOR SKIN EXTERNAL USE CONTAINING SALT OF ASCORBIC ACID DERIVATIVE, METHOD FOR STABILIZING THE AGENT FOR SKIN EXTERNAL USE, AND STABILIZER SHOWA DENKO K.K. (JP) 2005-04-21 WO disclosed
WO-2005020950-A1 COSMETIC COMPOSITION COMPRISING A AND A LIPOPEPTIDE SHOWA DENKO K.K. (JP) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197672-A1 COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS TYR, ATG7, BECN1 FFAR4 4514/4885FFAR1 4168/4885GPR84 3246/4885
US-20060222616-A1 Cosmetic composition comprising a and a lipopeptide CUTA, SMURF1, FABP4 FFAR4 73/4885FFAR1 22/4885GPR84 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.